PIERIS PHARMACEUTICALS, INC. License Agreements

7 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Amendment No. 1, dated March 29, 2021, to the Non-Exclusive Anticalin Platform License Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB
License Agreements
PIERIS PHARMACEUTICALS, INC.
Biotechnology
2021
Exclusive Product License Agreement, dated April 24, 2021, by and among Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH and BP Asset XII, Inc
License Agreements
PIERIS PHARMACEUTICALS, INC.
Biotechnology
2021
NON-EXCLUSIVE ANTICALIN® PLATFORM TECHNOLOGY LICENSE AGREEMENT
License Agreements
PIERIS PHARMACEUTICALS, INC.
Biotechnology
2017
AMENDMENT NO. 1 TO DEFINITIVE LICENSE AND TRANSFER AGREEMENT
License Agreements
PIERIS PHARMACEUTICALS, INC.
Biotechnology
2017
CONFIDENTIAL TREATMENT REQUESTED DEFINITIVE LICENSE ANDTRANSFER AGREEMENT
License Agreements
PIERIS PHARMACEUTICALS, INC.
Biotechnology
NY
2016
CONFIDENTIAL TREATMENT REQUESTED LICENSE AND TRANSFER AGREEMENT
License Agreements
PIERIS PHARMACEUTICALS, INC.
Biotechnology
NY
2016
CONFIDENTIAL TREATMENT REQUESTED SIDE AGREEMENT to theCollaboration and License Agreement between Sanofi, Sanofi-Pasteur and Pieris
License Agreements
PIERIS PHARMACEUTICALS, INC.
Biotechnology
2015